Enzypep

Year of investment: 2014

Enzypep developed a breakthrough technology for the synthesis of peptides using enzymes. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner.

QC Polymers

Year of investment: 2014

QC Polymers operates a polymer recycling plant with a nameplate capacity of 50,000 tons/year in Sittard-Geleen to produce polyethylene and polypropylene compounds from post-consumer and post-industrial waste. Typical applications are bottles, crates, pipes and automotive parts.

Q Chip

Year of investment: 2011

Q Chip, based in Cardiff (Wales, UK) commercializes innovative sustained-release drug formulations of injectable therapeutics. The sustained- release can be tailored and administration of the therapeutics is improved. The company was acquired by Midatech Pharma plc in late 2014.

Ekompany Agro

Year of investment: 2011

Ekompany Agro is a manufacturer of controlled release fertilizers using a proprietary and patented process. The company operates a 60,000 ton/year name plate capacity coated fertilizer plant and integrated 150,000 ton blending plant in Born (Netherlands). The assets were acquired by Shandong Kingenta Ecological Engineering early 2016.

TiGenix

Year of investment: 2009

TiGenix is a late-stage regenerative medicine company active in tissue engineering (cartilage repair) and allogeneic cell therapy. It has a marketing agreement with Sobi AB for its ChrondroCelect product in Europe. Its cell therapy products are in advanced stages of clinical trials. TiGenix NV is listed at Euronext Brussels.

Magnamedics

Year of investment: 2008

MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customers active in high-throughput screening of biomarkers. In 2014 the shares of Limburg Ventures were sold to the other shareholders.

Isobionics

Year of investment: 2008

Isobionics is a company that uses a proprietary biotechnology process for the production of flavor and fragrance ingredients. Its focus is on isoprenoid-based products for food, beverage, flavor and fragrance markets. The biotechnology process delivers products with higher quality and purity, at lower production cost.

Pharmacell

Year of investment: 2007

PharmaCell is world leader in cell-culturing services using its GMP-certified manufacturing facilities in Maastricht and Geleen. Its customers include the world leaders in commercial cell therapy products. Pharmacell has access to an extensive network which gives it the capability to provide support and/or partnership to R&D companies to bring new products from the lab into the clinic.

Oxford Performance Materials

Year of investment: 2006

Oxford Performance Materials supplies its versatile OXPEKK® polymers to space and defense, medical, semiconductor, and industrial markets worldwide. The company was sold to Arkema in early 2009.

Polyscope

Year of investment: 2006

Polyscope Polymers is a supplier of SMA copolymers for the automotive, paper and construction industries. Its engineering plastics compounds are sold primarily to the automotive industry for e.g. instrument panels and roof frames. Its low molecular grades, low and high MA content grades, liquid forms and imidized products find applications in many specialty markets. The company is based at the Chemelot site where it also has its production assets.